Altimmune Inc.’s pemvidutide has shown promising efficacy in a Phase II non-diabetic obesity trial but investors have been spooked by the rate of treatment discontinuations associated with adverse events, although analysts agreed safety concerns were overblown.
Pemvidutide is a GLP-1/glucagon dual receptor agonist in development for the treatment of obesity and non-alcohol related steatohepatitis (NASH). Its...